It’s been a crucial week for Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP); here’s what analysts have to say.

October 2, 2018 - By Linda Rogers

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Ratings Coverage

Among 4 analysts covering Aquinox Pharmaceuticals (NASDAQ:AQXP), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Aquinox Pharmaceuticals had 6 analyst reports since May 8, 2018 according to SRatingsIntel. The company was downgraded on Thursday, June 28 by Guggenheim. As per Tuesday, May 8, the company rating was maintained by Cantor Fitzgerald. The firm has “Neutral” rating by Cantor Fitzgerald given on Wednesday, June 27. The firm earned “Buy” rating on Monday, May 14 by Canaccord Genuity. The rating was downgraded by Canaccord Genuity to “Hold” on Thursday, June 28. Needham downgraded the shares of AQXP in report on Thursday, June 28 to “Hold” rating. Below is a list of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) latest ratings and price target changes.

28/06/2018 Broker: Needham Old Rating: Buy New Rating: Hold Downgrade
28/06/2018 Broker: Guggenheim Old Rating: Buy New Rating: Neutral Old Target: $26 Downgrade
28/06/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Hold Old Target: $22 New Target: $3 Downgrade
27/06/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Neutral Downgrade
14/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $22.0000 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $28.0000 Maintain

The stock decreased 2.45% or $0.07 during the last trading session, reaching $2.79. About 116,860 shares traded. Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has declined 80.33% since October 2, 2017 and is downtrending. It has underperformed by 95.95% the S&P500.

Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The company has market cap of $65.67 million. The firm primarily focuses on anti-inflammatory product candidates targeting SH2-containing inositol-5Â’-phosphatase 1 enzyme, a key regulator of a cellular signaling pathway in immune cells. It currently has negative earnings. The Company’s lead product candidate is AQX-1125, a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome, a chronic inflammatory disease of the bladder.

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: